227 related articles for article (PubMed ID: 12871322)
1. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX.
He S; Blombäck M; Jacobsson Ekman G; Hedner U
J Thromb Haemost; 2003 Jun; 1(6):1215-9. PubMed ID: 12871322
[TBL] [Abstract][Full Text] [Related]
2. General haemostatic agents--fact or fiction?
Hedner U
Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():33-6. PubMed ID: 12214145
[TBL] [Abstract][Full Text] [Related]
3. The effect of platelets on fibrin gel structure formed in the presence of recombinant factor VIIa in hemophilia plasma and in plasma from a patient with Glanzmann thrombasthenia.
He S; Ekman GJ; Hedner U
J Thromb Haemost; 2005 Feb; 3(2):272-9. PubMed ID: 15670032
[TBL] [Abstract][Full Text] [Related]
4. Prerequisites for recombinant factor VIIa-induced thrombin generation in plasmas deficient in factors VIII, IX or XI.
Livnat T; Zivelin A; Martinowitz U; Salomon O; Seligsohn U
J Thromb Haemost; 2006 Jan; 4(1):192-200. PubMed ID: 16409469
[TBL] [Abstract][Full Text] [Related]
5. Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion.
Carr ME; Martin EJ; Kuhn JG; Seremetis SV
Thromb Haemost; 2003 May; 89(5):803-11. PubMed ID: 12719776
[TBL] [Abstract][Full Text] [Related]
6. Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking.
Beckman JD; Holle LA; Wolberg AS
J Thromb Haemost; 2018 Jan; 16(1):131-141. PubMed ID: 29080382
[TBL] [Abstract][Full Text] [Related]
7. Potential role of recombinant factor VIIa as a hemostatic agent.
Hedner U; Erhardtsen E
Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
[TBL] [Abstract][Full Text] [Related]
8. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
[TBL] [Abstract][Full Text] [Related]
9. Recombinant factor VIIa analog NN1731 (V158D/E296V/M298Q-FVIIa) enhances fibrin formation, structure and stability in lipidated hemophilic plasma.
Gray LD; Hussey MA; Larson BM; Machlus KR; Campbell RA; Koch G; Ezban M; Hedner U; Wolberg AS
Thromb Res; 2011 Dec; 128(6):570-6. PubMed ID: 21561645
[TBL] [Abstract][Full Text] [Related]
10. Does recombinant factor VIIa, apart from overall hemostasis, regulate TAFI dependent fibrinolysis? In vitro analysis using overall hemostasis potential (OHP) assay.
Antovic JP; Antovic A
Thromb Haemost; 2003 Oct; 90(4):620-7. PubMed ID: 14515182
[TBL] [Abstract][Full Text] [Related]
11. Thrombin generation and platelet activation induced by rFVIIa (NovoSeven) and NN1731 in a reconstituted cell-based model mimicking haemophilia conditions.
Aljamali MN; Kjalke M; Hedner U; Ezban M; Tranholm M
Haemophilia; 2009 Nov; 15(6):1318-26. PubMed ID: 19659796
[TBL] [Abstract][Full Text] [Related]
12. Recombinant factor VIIa addition to haemophilic blood perfused over collagen/tissue factor can sufficiently bypass the factor IXa/VIIIa defect to rescue fibrin generation.
Li R; Panckeri KA; Fogarty PF; Cuker A; Diamond SL
Haemophilia; 2017 Sep; 23(5):759-768. PubMed ID: 28475272
[TBL] [Abstract][Full Text] [Related]
13. High dose factor VIIa improves clot structure and stability in a model of haemophilia B.
Wolberg AS; Allen GA; Monroe DM; Hedner U; Roberts HR; Hoffman M
Br J Haematol; 2005 Dec; 131(5):645-55. PubMed ID: 16351642
[TBL] [Abstract][Full Text] [Related]
14. Recombinant factor VIIa: its background, development and clinical use.
Hedner U
Curr Opin Hematol; 2007 May; 14(3):225-9. PubMed ID: 17414211
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human factor VIIa (rFVIIa) can activate factor FIX on activated platelets.
Gabriel DA; Li X; Monroe DM; Roberts HR
J Thromb Haemost; 2004 Oct; 2(10):1816-22. PubMed ID: 15456494
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of action, development and clinical experience of recombinant FVIIa.
Hedner U
J Biotechnol; 2006 Aug; 124(4):747-57. PubMed ID: 16697480
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of action of factor VIIa in the treatment of coagulopathies.
Hedner U
Semin Thromb Hemost; 2006 Apr; 32 Suppl 1():77-85. PubMed ID: 16673269
[TBL] [Abstract][Full Text] [Related]
18. New insights into the coagulation system and implications for new therapeutic options with recombinant factor VIIa.
Veldman A; Hoffman M; Ehrenforth S
Curr Med Chem; 2003 May; 10(10):797-811. PubMed ID: 12678684
[TBL] [Abstract][Full Text] [Related]
19. Effect of activated recombinant human factor 7 (Niastase) on laboratory testing of inhibitors of factors VIII and IX.
Keeney M; Allan DS; Lohmann RC; Yee IH
Lab Hematol; 2005; 11(2):118-23. PubMed ID: 16024335
[TBL] [Abstract][Full Text] [Related]
20. Recombinant factor VIIa enhances platelet deposition from flowing haemophilic blood but requires the contact pathway to promote fibrin deposition.
Li R; Panckeri KA; Fogarty PF; Diamond SL
Haemophilia; 2015 Mar; 21(2):266-274. PubMed ID: 25311576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
